A KL/R / AN A K/O / P O G G
|
|
- Rolf Nichols
- 5 years ago
- Views:
Transcription
1 Outline and New Treatments on the Horizon Steven R. Cummings, MD CPMC and UCSF San Francisco Coordinating Center Support from Lilly and Amgen New treatments, new mechanisms of action Cathepsin K inhibition Anti-sclerostin antibodies Muscle anabolics The //OPG system Part of TNF family is a membrane-bound bound and circulating protein : the receptor for OPG: circulating decoy receptor for Page 1
2 Rank-ligand binds to Rank (receptor) producing and activating osteoclasts Rank-ligand binds to Rank (receptor) producing and activating osteoclasts Adapted from Boyle et al. Nature. 23;423:337. Adapted from Boyle et al. Nature. 23;423:337. Rank-ligand binds to Rank (receptor) producing and activating osteoclasts Rank-ligand binds to Rank (receptor) producing and activating osteoclasts Differentiation & fusion Differentiation & fusion Active osteoclasts Adapted from Boyle et al. Nature. 23;423:337. Adapted from Boyle et al. Nature. 23;423:337. Page 2
3 OPG binds to RankL, inhibiting osteoclast development and activity OPG binds to RankL, inhibiting osteoclast development and activity OPG OPG Adapted from Boyle et al. Nature. 23;423:337. Adapted from Boyle et al. Nature. 23;423:337. OPG binds to RankL, inhibiting osteoclast development and activity OPG binds to RankL, inhibiting osteoclast development and activity OPG OPG Differentiation & fusion Differentiation & fusion s Adapted from Boyle et al. Nature. 23;423:337. Adapted from Boyle et al. Nature. 23;423:337. Page 3
4 (like OPG) binds -ligand, blocking its action (like OPG) binds -ligand, blocking its action Decreased differentiation & fusion Decreased osteoclasts Decreased differentiation & fusion Decreased osteoclasts Decreased resorption Decreased resorption Adapted from Boyle et al. Nature. 23;423:337. Adapted from Boyle et al. Nature. 23;423:337. (like OPG) binds -ligand, blocking its action Phase II Trial Decreased differentiation & fusion Decreased osteoclasts 412 postmenopausal women randomly assigned to 7 denosumab groups Q3 and Q mo intervals 4 different doses of Anti-RankL Antibody Alendronate 7 mg/d BMD and markers of bone turnover at 12 months Decreased resorption Adapted from Boyle et al. Nature. 23;423:337. McClung et al, NEJM 2; 354:821 Page 4
5 vs. Alendronate vs. vs. Alendronate vs. Alendronate Alendronate McClung et al, NEJM 2; 354:821 McClung et al, NEJM 2; 354:821 Stopping and restarting denosumab Effects of stopping and restarting denosumab Off On Off On P. Miller, et al, Bone 28;43:222-9 P. Miller, et al, Bone 28;43:222-9 Page 5
6 Study design: Subjects: The FREEDOM Trial Randomized trial Anti-RankL Ab mg or placebo SC every months for 3 months Plus 4-8 IU vitamin D and 1 g of calcium Postmenopausal women aged to 9 years Spine or hip T-score < -2.5 Cummings, et al. NEJM 29;31:75 Percent Change Substudy, N=1 Decrease in Serum CTX-I 8% relative reduction at month 1 Antibody Study Month 72% P<.1 Cummings, et al. NEJM 29;31:75 Percent Change BMD Changes at Total Hip 4 2 Antibody Study Month Substudy, N=1.% P<.1 Crude Incidence (%) Decreased New Vertebral Fracture 8% 95% CI (59 to 74%) P<.1 7.2% 2.3% Antibody Clinical vertebral fractures were also reduced 9%; P<.1 Cummings, et al. NEJM 29;31:75 Cummings, et al. NEJM 29;31:75 Page
7 Cumulative Incidence (%) Nonvertebral Fractures 8.%.5% Study Month 2% P=.11 95% CI, (5 to 33%) Cummings, et al. NEJM 29;31:75 is more effective for nonvertebral fracture in women with FN T-scores -2.5 Subgroup Overall Age (yea rs) < Body Mass I nde x (kg/m 2 ) < to < 3 3 Femoralneck BMD T-score Š -2.5 > -2.5 Prevalen t vertebral fracture Yes No Prior nonverteb ral fracture Yes No N SF McClung, Coordinating preparation Center HR (95% CI).8 (.7,.95).78 (.3,.9).84 (.3, 1.12).2 (.48,.8).98 (.75, 1.3) 1.13 (.71, 1.78).5 (.51,.83).97 (.7, 1.23) 1. (.78, 1.44).71 (.58,.88).84 (.5, 1.9).77 (.2,.97) Interaction P-value % Favors Cumulative Incidence (%) Hip Fracture Rates represent Kaplan-Meier estimates at 3 months 1.2%.7% Study Month 4% P=.3 95% CI (3 to 3%) Cummings, et al. NEJM 29;31:75 No increases in risk of Safety Impaired fracture healing, CVD, infections, cancer No ONJ in the osteoporosis trial (cases have been seen with treatment in patients with breast cancer) Increased Cellulitis (requiring hospital care): 3/1, Atopic dermatitis: ~1% more than placebo Cummings, et al. NEJM 29;31:75 Page 7
8 FDA approved indication for Women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fractures or patients who have failed or are intolerant to other available therapy in Men With Non-Metastatic Prostate Cancer Receiving ADT 148 men Undergoing bilateral orchiectomy or starting GnRH agonists Randomized to Anti-RankL Antibody mg or placebo SC every months for 3 months Smith et al. NEJM 29;31:745 Decreased risk of new vertebral fracture 4 2 Month 12 (N=73) RR.15 P=.4 Month 24 RR.31 P=.4 Antibody (N=79) Month 3 RR.38 P=. is critical to survival and evolution of the species causes breasts to develop and lactate during pregnancy causes resorption of bone to supply calcium for the milk No - pups die of starvation Percentage 1.9%.3% of Subjects 3.3% (%) 1.% % 1.5% 2 1 Smith et al. NEJM 29;31:745 Page 8
9 Cathepsin K Inhibitor Odanacatib Cathepsin K produced by osteoclasts, is released during bone resorption and degrades collagen Blocking Cathepsin K produces shallower resorption pits ODN is an antiresorptive Does it permit formation? (Uncoupling) Blocks the resorption of proteins which limits bone resorption to shallow pits. Theoretically, this would decrease resorption a little, but would allow full bone formation. Does it promote more formation than resorption? Geometric Mean Percent Change from Baseline s-bsap Month Month ODN 3 mg ODN 1 mg ODN 25 mg s-p1np ODN 5 mg SE = Standard error Page 9
10 Change in BMD over 3 months Transient rebound increase in bone resorption when treatment is stopped Lumbar Spine BMD (vs. baseline, %) Femoral Neck BMD (vs. baseline, %) Serum CTx (vs. baseline, %) Urine NTx (vs. baseline, %) Mean Percent Change From Baseline / 5 mg/ 5 mg/5 mg Month Mean Percent Change From Baseline / 5 mg/ 5 mg/5 mg Month Geometric Mean Percent Change from Baseline W1 3 / 5 mg/ 5 mg/5 mg Month Geometric Mean Percent Change from Baseline W1 3 / 5 mg/ 5 mg/5 mg Month Eisman et al, ASBMR 29 Eisman et al, ASBMR 29 The Osteocyte Network The largest organ in the body Anti-sclerostin antibodies J Feng and LF Bonewald, UMKC (Seeman, E, NEJM, 2) Page 1
11 Strain Osteocytes receive signals (e.g. strain) then send signals d to osteoclasts and osteoblasts on the surface of bone Produced by mature osteocytes Not found in any other cell Produced in response to decreased loading Inhibits the formation of osteoblasts Sclerostin From Lynda Bonewald Sclerosteosis: lack of sclerostin Sclerosteosis Very high bone mass Narrowing of neural foramina Can increase intracranial pressure causing death Due to mutations in the SOST gene, decreasing the production of biologically active sclerostin Page 11
12 % Change from Baseline (Mean ± SEM) Single doses of 5 & 1 mg/kg Scl mab increased P1NP (formation) and decreased sctx (resorption) 5 mg/kg (N=) 25 PINP CTX Time (day) 48 healthy postmenopausal women % Change from Baseline (Mean ± SEM) mg/kg (N=) Time (day) Mean % Change from Baseline In healthy postmenopausal women, scl mab increased spine BMD 5-% and hip BMD 3-4% in < 3 months Pbo Spine Time (day) 84 days (N=7) 1 mg/kg (N=) 3 mg/kg (N=) 5 mg/kg (N=) 1 mg/kg (N=) Scl Ab 48 healthy postmenopausal women Total Hip Time (day) Pbo 84 days Scl Ab Forms new bone on quiescent surfaces Anti-sclerostin antibodies In general, osteoblasts form bone where it has been reabsorbed But anti-sclerostin antibodies induce formation of bone on quiet surfaces, such as the periosteum This increases the diameter - and bending strength - of long bones The most potent bone forming agent yet discovered Has the potential to rapidly restore bone mass and architecture to normal Highly specific to bone Human trials are in phase II Page 12
13 Myostatin Increasing muscle and bone mass Myostatin inhibits development and differentiation of muscle cells Animals with myostatin mutations (or knock-outs) outs) have much more muscle! Blocking myostatin increases callus formation and fracture healing The potential of Myostatin antibodies Mice Wild-type (WT) Myostatin KO Fractured fibula MSTN KO mice had more bone in callus at 2 and 4 weeks r Ideal for recovery after fracture May have added benefits of improved insulin sensitivity and cardiac function Anti-myostatin antibodies in early human trials An example new interventions that act on fundamental pathways, (such as mitochondrial function), to preserve muscle, slow aging, and increase bone mass Kellum, Bone 29;44: Page 13
14 New treatments The new generation is based on fundamental mechanisms : the most potent antiresorptive yet Will odanacatib reduce nonvertebral fractures more than current treatments? Will anti-sclerostin antibodies cure osteoporosis? Will muscle building agents also build bone, prevent falls and dramatically decrease frailty fractures? Will we be able to afford new treatments? Page 14
7/5/2016. We need drugs that. Disclosures. New Osteoporosis Treatments. What we have today. Maintain or promote bone formation
New Osteoporosis Treatments Disclosures Mary L. Bouxsein, PhD Department of Orthopedic Surgery Harvard Medical School, Boston, MA Advisory Board: Research funding: Merck, Eli Lilly, Radius Merck, Amgen
More informationUpcoming Agents for Osteoporosis
Upcoming Agents for Osteoporosis May 5, 2017 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Professorial Fellow, Institute of Health and Ageing Australian Catholic
More informationAssessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationAn Update on Osteoporosis Treatments
An Update on Osteoporosis Treatments Dr Mike Stone University Hospital Llandough Treatments for osteoporosis Calcium and vitamin D HRT Raloxifene Etidronate Alendronate Risedronate Ibandronate (oral and
More informationNEW HORIZONS IN OSTEOPOROSIS THERAPY. Sundeep Khosla, M.D. Mayo Clinic, Rochester, MN
NEW HORIZONS IN OSTEOPOROSIS THERAPY Sundeep Khosla, M.D. Mayo Clinic, Rochester, MN DISCLOSURES SUNDEEP KHOSLA, M.D. Investigator-initiated grant Merck No non-fda approved recommendations RISK ASSESSMENT
More informationUpdates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationOsteoporosis update. Dr. Claire Vandevelde Consultant Rheumatologist, LTHT
Osteoporosis update Dr. Claire Vandevelde Consultant Rheumatologist, LTHT Outline Background BMD Tools for assessing fracture risk Case study Denosumab Treatment breaks BMD BMD predicts fracture risk but
More informationPage 1. Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco What s
More informationHRT and Risedronate Combined Anabolic and Antiresorptive Therapy
Optimizing Combined and Sequential Osteoanabolic and Antiresorptive Therapy Benjamin Leder, M.D. Endocrine Unit Massachusetts General Hospital Boston, MA Antiresorptive and Osteoanabolic Therapies Increase
More informationOsteoporosis: current treatment and future prospects. Juliet Compston Professor Emeritus of Bone Medicine Cambridge Biomedical Campus
Osteoporosis: current treatment and future prospects Juliet Compston Professor Emeritus of Bone Medicine Cambridge Biomedical Campus Disclosures Consultancy and speaking fees for Gilead, related to development
More informationOsteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
More informationDiagnosis and Treatment of Osteoporosis: What s New and Controversial in ? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018-19? What s New in Osteoporosis The crisis in treatment and compliance Douglas C. Bauer, MD Professor of Medicine and Epidemiology
More informationSummary. Treatment. a larger extent than predicted. spine much faster and to. that fracture protection is greater
The Future of Ost eoporosis Care in Research and Practice ACOI Luncheon October 26, 2010 Steven T Harris MD FACP Clinical i l Profess sor of fmedicine i University of California, San Francisco Treatment
More informationOsteoporosis - Pathophysiology and diagnosis. Bente L Langdahl Department of Endocrinology Aarhus University Hospital Aarhus, Denmark
Osteoporosis - Pathophysiology and diagnosis Bente L Langdahl Department of Endocrinology Aarhus University Hospital Aarhus, Denmark Objective General knowledge about osteoporosis Optimise your protocols
More informationMs. Y. Outline. Updates of SERMs and Estrogen
Ms. Y Updates of SERMs and Estrogen Steven R. Cummings, MD, FACP San Francisco Coordinating Center CPMC Research Institute and UCSF Support from Lilly, Pfizer, Berlex 55 y.o. woman with mild hypertension
More informationNew Therapeutic Directions: Osteoanabolic and Antiresorptive Therapy in Combination Therapy and in Sequence
New Therapeutic Directions: Osteoanabolic and Antiresorptive Therapy in Combination Therapy and in Sequence John P. Bilezikian, MD, PhD(hon), MACE Silberberg Professor of Medicine Vice-Chair for International
More informationDifferentiating Pharmacological Therapies for Osteoporosis
Differentiating Pharmacological Therapies for Osteoporosis Socrates E Papapoulos Department of Endocrinology & Metabolic Diseases Leiden University Medical Center The Netherlands Competing interests: consulting/speaking
More informationOSTEONECROSI DEI MASCELLARI (ONJ): PREVENZIONE, DIAGNOSI, TRATTAMENTO UPDATE 2010
OSTEONECROSI DEI MASCELLARI (ONJ): PREVENZIONE, DIAGNOSI, TRATTAMENTO UPDATE 2010 Alessandria, 5 giugno 2010 Novità nel trattamento dell osteoporosi Stefania Boldini Francesco Bertoldo Dipartimento di
More informationOsteoporosis 2017 Breaking News. Julie L. Carkin, MD The Seattle Arthritis Clinic
Osteoporosis 2017 Breaking News Julie L. Carkin, MD The Seattle Arthritis Clinic 1 Yes, Hopefully & No Anabolic Teriparatide Abaloparatide Romosozumab blosozumab Anti-catabolic Bisphosphonates Denosumab
More information2017 Santa Fe Bone Symposium McClung
217 Santa Fe Bone Symposium Insights into the Use of Anti-remodeling and Anabolic Agents for Osteoporosis Developing a Long-term Management Plan Michael R., MD, FACP Oregon Osteoporosis Center Portland,
More informationDownload slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Biochemical Markers of Bone Turnover: Definitions and Recommendations for Monitoring Therapy Learning Objectives for Biochemical
More informationLong-term Osteoporosis Therapy What To Do After 5 Years?
Long-term Osteoporosis Therapy What To Do After 5 Years? Developing a Long-term Management Plan North American Menopause Society Philadelphia, PA October 11, 2017 Michael R. McClung, MD, FACP Institute
More informationTREATING OSTEOPOROSIS IN 2018: WHAT'S OLD, WHAT'S NEW, WHAT'S UNPROVEN AND WHAT'S TRUE. Nelson B. Watts, MD
TREATING OSTEOPOROSIS IN 2018: WHAT'S OLD, WHAT'S NEW, WHAT'S UNPROVEN AND WHAT'S TRUE Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO Honoraria: Amgen, Radius, Shire Consulting
More informationAACE. Orlando Drug Holidays. Disclosures. Advisory boards: Alexion, Amgen, Lilly, Merck, Radius Health
AACE Orlando 2016 Drug Holidays Disclosures Advisory boards: Alexion, Amgen, Lilly, Merck, Radius Health Scientific grants: Alexion, Amgen, Immunodiagnostics, Lilly, Merck, Regeneron, Radius Health, Roche
More informationUpdates in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationChau Nguyen, D.O. Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences
Chau Nguyen, D.O Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences I do not have any relationship with the manufacturer of any commercial products
More informationPage 1. Current and Emerging Strategies What s New in Osteoporosis. Osteoporosis. What is Osteoporosis? Traditional Risk Factors for Fracture
Current and Emerging Strategies for Osteoporosis What s New in Osteoporosis Risk stratification Douglas C. Bauer, MD University of California, San Francisco Under recognition and poor compliance New potential
More informationCurrent Issues in Osteoporosis
Current Issues in Osteoporosis California AACE 18TH Annual Meeting & Symposium Marina del Rey, CA September 15, 2018 Michael R. McClung, MD, FACP,FACE Director, Oregon Osteoporosis Center Portland, Oregon,
More informationOutline. Estrogens and SERMS The forgotten few! How Does Estrogen Work in Bone? Its Complex!!! 6/14/2013
Outline Estrogens and SERMS The forgotten few! Clifford J Rosen MD rosenc@mmc.org Physiology of Estrogen and estrogen receptors Actions of estrogen on bone BMD, fracture, other off target effects Cohort
More informationControversies in Osteoporosis Management
Controversies in Osteoporosis Management 2018 Northwest Rheumatism Society Meeting Portland, OR April 28, 2018 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Institute
More informationAdvanced medicine conference. Monday 20 Tuesday 21 June 2016
Advanced medicine conference Monday 20 Tuesday 21 June 2016 Osteoporosis: recent advances in risk assessment and management Juliet Compston Emeritus Professor of Bone Medicine Cambridge Biomedical Campus
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationBeyond Bisphosphonates: Future Osteoporosis Therapies
Beyond Bisphosphonates: Future Osteoporosis Therapies Clifford Rosen MD rosenc@mmc.org 1 No Conflicts of Interest 2 Outline What s the evidence for bisphosphonates and why not? Clinical trials with bisphosphonatesfracture
More informationPresenter: 翁家嫻 Venue date:
FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT INCREASED RISK OF FRACTURES 1 Presenter: 翁家嫻 Venue date: 2018.03.13 PMO: postmenopausal osteoporosis. 1. Prolia (denosumab), Summary of Product
More informationPHARMACOLOGIC PROPERTIES
Denosumab Prolia TM 60mg/mL Solution for Injection PRODUCT DESCRIPTION Each pre-filled syringe contains 60 mg of denosumab in 1.0 ml solution (60 mg/ml). Clear, colourless to slightly yellow solution,
More informationDisclosures D. Black. Bisphosphonates: Background, Efficacy and Recent Controversies. Page 1. Research Funding: Novartis, Merck
Bisphosphonates: Background, Efficacy and Recent Controversies Disclosures D. Black Research Funding: Novartis, Merck Dennis M. Black, PhD Consulting: Amgen, Lilly, Zosano, Nycomed Dept. of Epidemiology
More informationNew Developments in Osteoporosis: Screening, Prevention and Treatment
Osteoporosis: Overview New Developments in Osteoporosis: Screening, Prevention and Treatment Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Risk factors
More informationOsteoporosis Screening and Treatment in Type 2 Diabetes
Osteoporosis Screening and Treatment in Type 2 Diabetes Ann Schwartz, PhD! Dept. of Epidemiology and Biostatistics! University of California San Francisco! October 2011! Presenter Disclosure Information
More informationIntegrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options
Paris, November 1st 2016 Integrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options René Rizzoli MD International Osteoporosis Foundation and Division of Bone
More informationBased on review of available data, the Company may consider the use of denosumab (Prolia) for the
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationdenosumab (Prolia ) Policy # Original Effective Date: 07/21/2011 Current Effective Date: 04/19/2017
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationPathophysiology of Postmenopausal & Glucocorticoid Induced Osteoporosis. March 15, 2016 Bone ECHO Kate T Queen, MD
Pathophysiology of Postmenopausal & Glucocorticoid Induced Osteoporosis March 15, 2016 Bone ECHO Kate T Queen, MD Review: normal bone formation Bone Modeling Remodeling Peak Bone Mass Maximum bone mass
More informationTHE GROWING GAP IN OSTEOPOROSIS TREATMENT
THE GROWING GAP IN OSTEOPOROSIS TREATMENT Sundeep Khosla, M.D. Mayo Clinic, Rochester, MN DISCLOSURES SUNDEEP KHOSLA, M.D. NONE 1 OVERALL CONCLUSIONS There has been remarkable progress in our understanding
More informationCurrent and Emerging Approaches for Osteoporosis
Current and Emerging Approaches for Osteoporosis Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures What s New in Osteoporosis
More informationPharmacy Management Drug Policy
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationProduct: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1
Date: 21 November 2016 Page 1 2. SYNOPSIS Name of Sponsor: Amgen Inc., Thousand Oaks, CA, USA Name of Finished Product: Prolia Name of Active Ingredient: denosumab Title of Study: Randomized, Double-blind,
More informationNew treatment targets in osteoporosis
National University of Athens Greece New treatment targets in osteoporosis Gourzi Vassiliki PhD Candidate Dept. of Pathophysiology School of Medicine Bone remodeling Physiological process < bone tissue
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Prolia 60 mg solution for injection in a pre-filled syringe 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each pre-filled syringe
More informationAACE. Osteoporosis Treatment: Then and Now
AACE 25 th Annual Scientific and Clinical Congress Osteoporosis Treatment: Then and Now Orlando, FL May 28, 2016 Michael R. McClung, MD Oregon Osteoporosis Center Portland, Oregon, USA Disclosures I am
More informationOsteoporosis Agents Drug Class Prior Authorization Protocol
Osteoporosis Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More informationPage 1. Updates in Osteoporosis. I have no conflicts of interest. What is osteoporosis? What s New in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in Osteoporosis
More informationHot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis
Hot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis Aromatase Inhibitor-Induced Bone Loss in Early Breast Cancer Rachel Pessah-Pollack, M.D., F.A.C.E. Mount Sinai School
More informationBreast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime
Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy
More informationRefracture Prevention The Role of Primary Care
MonashHealth Refracture Prevention The Role of Primary Care Professor Peter R Ebeling AO MBBS MD FRACP Head, Department of Medicine School for Clinical Sciences Monash Health Translation Precinct Monash
More informationOsteoporosis in Men Professor Peter R Ebeling
Osteoporosis in Men MD FRACP Head, Department of Medicine, School for Clinical Sciences Monash Health Translation Precinct Monash University, Clayton, Victoria 1 MonashHealth Potential Conflicts Departmental
More informationAN OVERVIEW of TREATMENT: WHO and WHEN to TREAT
AN OVERVIEW of TREATMENT: WHO and WHEN to TREAT Dolores Shoback, MD Professor of Medicine, UCSF San Francisco VA Medical Center July 16, 21 ~ QUESTIONS ~ Who should receive therapy to prevent fractures?
More informationNAME OF THE MEDICINE. Prolia is the Amgen Inc. trademark for denosumab (rch). DESCRIPTION
Prolia (denosumab) Product Information Page 1 of 15 NAME OF THE MEDICINE Prolia is the Amgen Inc. trademark for denosumab (rch). DESCRIPTION Denosumab is a fully human IgG2 monoclonal antibody with high
More informationPage 1. New Developments in Osteoporosis. What s New in Osteoporosis
New Developments in Osteoporosis Eliseo J. Pérez-Stable MD Professor of Medicine Division of General Internal Medicine Department of Medicine July 4, 2013 Declaration of full disclosure: No conflict of
More informationCurrent and Emerging Strategies for Osteoporosis
Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis
More informationOsteoporosis for the PCP and consultant COPYRIGHT. Harold Rosen, MD Director- Osteoporosis Prevention and Treatment Center
Osteoporosis for the PCP and consultant Harold Rosen, MD Director- Osteoporosis Prevention and Treatment Center Beth Israel Deaconess Medical Center Potential conflicts of interest None GOALS When to screen/treat?
More informationVol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases
ה מ ר א פ הביטאון לענייני תרופות ISRAEL DRUG BULLETIN 19 years of unbiased and independent drug information P H A R x M A Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab
More informationUpdate on Osteoporosis 2016
WELCOME! Update on Osteoporosis 2016 Jennifer J. Kelly, D.O., F.A.C.E. Associate Professor of Medicine Division of Endocrinology, Diabetes and Metabolism Upstate Medical University Director of the Clinical
More informationOsteoporosis Management in Older Adults
Osteoporosis Management in Older Adults Angela M Cheung, MD, PhD, FRCPC, CCD Professor of Medicine, University of Toronto Disclosures Relationship with Commercial Entities: Honoraria from: Amgen, Eli Lilly,
More informationBad to the Bones: Diabetes and Thiazolidinediones 9/9/2010. Steven Ing, MD, MSCE Assistant Professor Division of Endocrinology, Diabetes & Metabolism
Bad to the Bones: Diabetes and Thiazolidinediones 9/9/2010 Steven Ing, MD, MSCE Assistant Professor Division of Endocrinology, Diabetes & Metabolism Any reduction of bone mass in diabetics that is revealed
More informationFrom Fragile to Firm. Monika Starosta MD. Advocate Medical Group
From Fragile to Firm Monika Starosta MD Advocate Medical Group Bone Remodeling 10% remodeled each year Calcium homoeostasis Maintain Mechanical strength Replace Osteocytes Release Growth Factors Bone remodeling
More informationMedication Associated Osteoporosis
Medication Associated Osteoporosis Drugs that are bad for the bones Jonathan Graf, MD Associate Professor of Clinical Medicine UCSF Director UCSF Rheumatoid Arthritis Clinic Necessary Therapies Preventable
More informationCalcium, Vitamin D and Bisphosphonates: Disclosures. Benefits, Risks and Drug Holiday. Calcium YES or NO? Calcium Bad News!!
Calcium, Vitamin D and Bisphosphonates: Benefits, Risks and Drug Holiday Disclosures I am disclosing financial relationships as follows: Global Advisory Boards: Amgen, Lilly, Merck, Novartis Research grants:
More informationPage 1. Osteoporosis Warm-Up: Which of the Following is True? Diagnosis and Treatment of Osteoporosis: What is New in What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What is New in 2017 Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures Osteoporosis
More informationTREATMENT OF OSTEOPOROSIS HOLIDAYS OR NO HOLIDAYS? Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
TREATMENT OF OSTEOPOROSIS HOLIDAYS OR NO HOLIDAYS? Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Honoraria: Amgen, Merck, Shire Consulting : AbbVie, Amgen, Merck,
More informationA Review of Bone Health Issues in Oncology
A Review of Bone Health Issues in Oncology David L. Kendler MD FRCPC CCD Professor of Medicine (Endocrinology) University of British Columbia Vancouver Canada Disclosures David Kendler has received research
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationOptimizing Osteoporosis Management Dr. Philip A. Baer Seacourses Asia CME December 2017
Optimizing Osteoporosis Management Dr. Philip A. Baer Seacourses Asia CME December 2017 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationUpdate in Osteoporosis: Disclosures. Topics
Update in Osteoporosis: 21 Michael Maricic, M.D. Catalina Pointe Rheumatogy Clinical Associate Professor of Medicine University of Arizona Disclosures Speakers Bureau, Consultant or Clinical Research Grant
More information52% 34% 5. Both 1) and 3) Start calcium... Both 1) and 3) Start alendron... Start raloxife... Page 1
New Developments in Osteoporosis Mary S. Beattie, MD, MAS, UCSF Women s Health Thanks to Douglas C. Bauer, MD What s New in Osteoporosis Absolute risk - FRAX Under recognition Poor compliance When to stop
More informationClinical Specialist Statement Template
Clinical Specialist Statement Template Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can
More informationOsteoporosis: An Overview. Carolyn J. Crandall, MD, MS
Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis
More informationPage 1. Current and Emerging Strategies for Osteoporosis. Osteoporosis Warm-Up: Which of the Following is True?
Current and Emerging Strategies for Osteoporosis Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures Osteoporosis Warm-Up:
More informationOutline. Switching treatment. Evidence from randomized trials. The effects of switching 7/8/2016. When and for whom? Steven Cummings, MD
Outline Switching treatment When and for whom? Steven Cummings, MD Focus on switching from alendronate or risedronate Evidence about the effects of switching on BMD Purposes of switching Symptoms Poor
More informationElderly men with prostate cancer + ADT
Elderly men with prostate cancer + ADT Background and Rationale ADT and Osteoporosis Proportion of Patients With Fractures 1-5 Yrs After Cancer Diagnosis 21 18 +6.8%; P
More informationRenata Caudarella. Fondazione Ettore Sansavini per la Ricerca Scientifica (Health Science Foundation ) - GVM Care & Research
Renata Caudarella Fondazione Ettore Sansavini per la Ricerca Scientifica (Health Science Foundation ) - GVM Care & Research Introduc/on During the past two decades, many randomized controlled trials (RCTs)
More informationNew therapies for osteoporosis. Dr.Shobhana Mohandas.MD.DGO.FICOG. Sun Medical centre, Thrissur, Kerala.
New therapies for osteoporosis Dr.Shobhana Mohandas.MD.DGO.FICOG. Sun Medical centre, Thrissur, Kerala. Osteoclastic resorption Sema 4 D Plexin B1 from osteo TGF-β1, and IGF-1 Osteoblast Migration Osteoblast
More informationNew treatments of osteoporosis
HOSTED BY Available online at www.sciencedirect.com ScienceDirect Osteoporosis and Sarcopenia 1 (2015) 4e21 Review article New treatments of osteoporosis http://www.elsevier.com/locate/afos Bente L. Langdahl
More informationOSTEOPOROSIS: PREVENTION AND MANAGEMENT
OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring
More informationHow to treat osteoporosis With what and for how long?
How to treat osteoporosis With what and for how long? Professor Neil Gittoes Consultant Endocrinologist & Honorary Professor Where will we be going? Drug therapies Current Indications Contraindications/unmet
More informationDenosumab (Prolia ) (TLS Amber)
Denosumab (Prolia ) (TLS Amber) Shared Care Guidelines: For the treatment of postmenopausal osteoporosis. AREAS OF RESPONSIBILITY FOR THE SHARING OF CARE This shared care agreement outlines suggested ways
More informationTEAM SCIENCE AT A PROGRAMMATIC LEVEL. Sundeep Khosla, M.D. Mayo Clinic College of Medicine
TEAM SCIENCE AT A PROGRAMMATIC LEVEL Sundeep Khosla, M.D. Mayo Clinic College of Medicine APPROACH TO TRANSLATIONAL RESEARCH IN OSTEOPOROSIS Epidemiological Studies Clinical Investigation Mouse and Cellular
More informationReview Article RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis
SAGE-Hindawi Access to Research Osteoporosis Volume 2011, Article ID 941310, 6 pages doi:10.4061/2011/941310 Review Article RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis
More informationMonitoring Osteoporosis Therapy
Monitoring Osteoporosis Therapy SUZANNE MORIN DEPT OF MEDICINE, DIVISION OF GENERAL INTERNAL MEDICINE, MUHC CENTRE FOR OUTCOMES RESEARCH AND EVALUATION, RI MUHC November 2017 Conflict of Interest Disclosures
More informationOsteoporosis Medications: A Case-Based Discussion. Laila S. Tabatabai, MD August 5, 2017
Osteoporosis Medications: A Case-Based Discussion Laila S. Tabatabai, MD August 5, 2017 Disclosures Eli Lilly Radius Objectives Determine which patients with low bone density require treatment, along with
More informationSERMS, Hormone Therapy and Calcitonin
SERMS, Hormone Therapy and Calcitonin Tiffany Kim, MD Clinical Fellow VA Advanced Women s Health UCSF Endocrinology and Metabolism I have nothing to disclose Thanks to Clifford Rosen and Steven Cummings
More informationLa salute dell osso nelle pazienti in trattamento adiuvante. Airoldi Mario - S.C. Oncologia Medica 2 Città della Salute e della Scienza di Torino
La salute dell osso nelle pazienti in trattamento adiuvante Airoldi Mario - S.C. Oncologia Medica 2 Città della Salute e della Scienza di Torino BONE STRENGTH OSTEOPOROSIS SKELETAL DISORDER COMPROMISING
More informationTraining Course in Sexual and Reproductive Health Research Geneva, February Osteoporosis. Prof René Rizzoli M.D.
Training Course in Sexual and Reproductive Health Research Geneva, February 17 2009 Osteoporosis Prof René Rizzoli M.D. Division of bone diseases WHO collaborating center for osteoporosis prevention Department
More informationName of Policy: Zoledronic Acid (Reclast ) Injection
Name of Policy: Zoledronic Acid (Reclast ) Injection Policy #: 355 Latest Review Date: May 2011 Category: Pharmacy Policy Grade: Active Policy but no longer scheduled for regular literature reviews and
More informationOptimizing Management of High Risk Osteoporosis
National Experts Illuminate and Debate Optimizing Management of High Risk Osteoporosis Focus on New Mechanisms and Evidence-Based Strategies for Fracture Prevention in High Risk, Postmenopausal Patients
More informationKristen M. Nebel, DO PENN/ LGHP Geriatrics. Temple Family Medicine Review
Kristen M. Nebel, DO PENN/ LGHP Geriatrics 10/3/17 Temple Family Medicine Review OBJECTIVES Define Revised 2017 American College of Physician Recommendations Screening, Prevention and Treatment Application
More information